BridgeBio: New Data on Novel Approaches to RAS-driven Cancers

 The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022

- Presentation to include details from next-generation G12C dual inhibitor clinical candidate and characterization of advanced leads from thePI3Kα:RAS breaker program

- BridgeBio will host an investor call on October 17, 2022 at 1:30 pm ET to discuss the data and next steps for its two lead RAS programs

- RAS is the most common oncogenic driver with approximately 30% of all human cancers being driven by RAS mutations, including large proportions of lung, colorectal and pancreatic tumors. PIK3CA is the second most common oncogene in human tumors, being present in more than 30% of breast and endometrial carcinomas.

Webcast Information
BridgeBio will host an investor call and simultaneous webcast to discuss preclinical data from both lead RAS programs and the selection of the KRAS G12C dual inhibitor development candidate on October 17, 2022 at 1:30 pm ET. To access this call via phone, participants will need to register using the following link where they will be provided a phone number and access code: (https://register.vevent.com/register/BIbd4d7a752dcc4ade970571556d4060e5). The webcast and presentation slides can be viewed during the time of the call via a link on the event calendar page of BridgeBio’s website at https://investor.bridgebio.com/. A replay of the conference call and webcast will be archived on the Company’s website and will be available for at least 30 days following the event. 

https://www.biospace.com/article/releases/bridgebio-pharma-to-present-new-data-on-its-novel-approaches-to-ras-driven-cancers-at-the-fourth-ras-initiative-symposium/